

# Inhibitor of Apoptosis Proteins as Novel Targets in Inflammatory Processes

Bettina A. Mayer, Markus Rehberg, Annette Erhardt, Alexander Wolf, Christoph A. Reichel, Michael Kracht, Fritz Krombach, Gisa Tiegs, Stefan Zahler, Angelika M. Vollmar, Robert Fürst

**Objective**—Inhibitor of apoptosis proteins (IAPs), such as X-linked or cellular IAP 1/2 (XIAP, cIAP1/2), are important regulators of apoptosis. IAP antagonists are currently under clinical investigation as anticancer agents. Interestingly, IAPs participate in the inflammation-associated TNF receptor signaling complex and regulate NF $\kappa$ B signaling. This raises the question about the role of IAPs in inflammation. Here, we investigated the anti-inflammatory potential of IAP inhibitors and the role of IAPs in inflammatory processes of endothelial cells.

**Methods and Results**—In mice, the small molecule IAP antagonist A-4.10099.1 (ABT) suppressed antigen-induced arthritis, leukocyte infiltration in concanavalin A-evoked liver injury, and leukocyte transmigration in the TNF $\alpha$ -activated cremaster muscle. In vitro, we observed an attenuation of leukocyte–endothelial cell interaction by downregulation of the intercellular adhesion molecule-1. ABT did not impair NF $\kappa$ B signaling but decreased the TNF $\alpha$ -induced activation of the TGF- $\beta$ -activated kinase 1, p38, and c-Jun N-terminal kinase. These effects are based on the proteasomal degradation of cIAP1/2 accompanied by an altered ratio of the levels of membrane-localized TNF receptor-associated factors 2 and 5.

**Conclusion**—Our results reveal IAP antagonism as a profound anti-inflammatory principle in vivo and highlight IAPs as important regulators of inflammatory processes in endothelial cells. (*Arterioscler Thromb Vasc Biol.* 2011;31:2240–2250.)

**Key Words:** Endothelium ■ Pharmacology ■ NF-kappaB ■ inflammation ■ inhibitor of apoptosis proteins (IAPs)

X-linked inhibitor of apoptosis protein (XIAP), cellular inhibitor of apoptosis protein-1 (cIAP1) and -2 (cIAP2) are the best characterized mammalian members of the inhibitor of apoptosis protein (IAP) family, whose common feature is the presence of baculoviral IAP repeat (BIR) domains. The IAPs, in particular XIAP, have been implicated in the regulation of cell death by interaction with caspases via their BIR domains.<sup>1,2</sup> Because IAPs are frequently overexpressed in human malignancies,<sup>3,4</sup> they became highly attractive targets for the development of promising anticancer therapeutics. One strategy to develop IAP-targeting compounds was based on the structure of the endogenous IAP antagonist Smac. The peptidic Smac mimetic ABT [compound 11 reported in Oost et al<sup>5</sup>], which we used as an experimental IAP inhibitor in this work, is a small molecule inhibitor modeled to bind to the BIR3 domain of XIAP with a nanomolar affinity and has successfully been used as an apoptosis-inducing compound in anticancer strategies.<sup>5</sup>

## See accompanying article on page 2165

In addition to its caspase-inhibiting function, XIAP is known to interact with NF $\kappa$ B and mitogen-activated protein

kinase (MAPK) signaling.<sup>6,7</sup> The cIAPs have been reported to participate in the TNF receptor (TNFR)-associated signaling complex where they are involved in the ubiquitin-mediated signaling and in the associated activation of NF $\kappa$ B.<sup>8–11</sup> Besides TNFR signaling, IAPs were found to be involved in TRAIL-R, CD40, BAFF-R, and nucleotide-binding and oligomerization domain-containing protein 1/2 signaling.<sup>12</sup> Moreover, recent publications indicate a regulatory role of IAPs in immune functions by controlling cell survival<sup>13</sup> or activation of immune cells. IAPs have been shown to regulate the cytokine production of macrophages via participating in the nucleotide-binding and oligomerization domain signaling,<sup>14</sup> and Bauler et al<sup>15</sup> has identified XIAP as a regulator of innate immunity to *Listeria* infections. These findings point toward a complex role of IAPs in cellular processes beyond the regulation of apoptosis.

The TNFR signaling is of utmost importance for the induction of a wide variety of inflammatory processes and their activation plays a crucial role in the pathogenesis and progression of many severe disorders, such as atherosclerosis, arthritis, or sepsis.<sup>16</sup> One hallmark of inflammation is the

Received on: November 3, 2010; final version accepted on: July 21, 2011.

From the Munich Center for System-Based Drug Research, Department of Pharmacy (B.A.M., S.Z., A.M.V., R.F.) and the Walter-Brendel-Center of Experimental Medicine (M.R., C.A.R., F.K.), University of Munich, Munich, Germany; Institute of Experimental Immunology and Hepatology (A.E., G.T.), University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Rudolf-Buchheim-Institute of Pharmacology (A.W., M.K.), University of Giessen, Giessen, Germany.

Correspondence to Robert Fürst, Munich Center for System-Based Drug Research, Department of Pharmacy, University of Munich, Butenandtstr. 5-13, 81377 Munich, Germany. E-mail robert.fuerst@cup.uni-muenchen.de

© 2011 American Heart Association, Inc.

*Arterioscler Thromb Vasc Biol* is available at <http://atvb.ahajournals.org>

DOI: 10.1161/ATVBAHA.111.234294

extravasation of circulating leukocytes from the blood into the inflamed tissue. The endothelium tightly regulates and, on activation by proinflammatory stimuli, such as TNF $\alpha$ , strongly promotes this process and is thus a crucial player in inflammation.

We inferred from the existing knowledge that IAPs could be crucial mediators of inflammation and that IAP antagonists might thus exert anti-inflammatory actions. Consequently, we analyzed the general capability of IAP inhibition to influence inflammation *in vivo* and investigated the underlying molecular mechanisms of action *in vitro* in endothelial cells (ECs).

## Methods

An expanded version of this section can be found in the supplemental material available at <http://atvb.ahajournals.org>.

### Smac Mimetics

A-4.10099.1 (ABT) [compound 11 reported in Oost et al<sup>5</sup>] was kindly provided by Abbott Bioresearch Corporation, Worcester, MA. The monomeric compound Smac066 [compound 40d reported in Seneci et al<sup>17</sup>] and the dimeric Smac085 (unpublished) were kindly provided by the group of Prof. Pierfausto Seneci (Department of Organic and Industrial Chemistry, University of Milano, Milan, Italy).

### Animals

All experiments were performed with male C57BL/6 mice (Charles River, Sulzfeld, Germany) according to the German legislation for the protection of animals and approved by the local governmental authorities.

### Murine Antigen-Induced Arthritis

The antigen-induced arthritis experiment was performed as previously described by Veiheilmann et al.<sup>18</sup> Briefly, mice were immunized against methylated bovine serum albumin (Sigma-Aldrich, Taufkirchen, Germany) and arthritis was induced by injection of methylated bovine serum albumin into the left knee joint.

### Concanavalin A-Induced Murine Hepatitis

The model has been described previously in detail.<sup>19</sup> Briefly, concanavalin A (ConA; Sigma-Aldrich) was administered to mice intravenously at 15 mg/kg. One  $\mu$ g ABT was administered intravenously 15 minutes before ConA. Mice were euthanized 8 hours after ConA application. Plasma enzyme activity of alanine aminotransferase was assessed using an automated procedure with COBAS MIRA (Roche, Basel, Switzerland). Liver tissue paraffin sections were stained with a naphthol-AS-D-chloroacetate-esterase kit (Sigma-Aldrich).

### Analysis of Leukocyte Adhesion and Transmigration by Intravital Microscopy of the Mouse Cremaster Muscle

The surgical preparation of the cremaster muscle and the intravital microscopy were performed as described by Baez.<sup>20</sup>

### Cell Culture and Media

Primary human umbilical vein endothelial cells (HUVECs) were isolated from umbilical cords. HUVECs and HeLa cells were cultured as previously described.<sup>21,22</sup> Human neutrophil granulocytes were separated from heparinized peripheral blood of healthy volunteers by using CD15 MicroBeads (Miltenyi, Bergisch Gladbach, Germany).

### Granulocyte Adhesion Assay

Neutrophil granulocytes were added to confluent HUVECs that were pretreated or not with CD54 blocking antibody/isotype control

(Biolegend, San Diego, CA) and allowed to adhere for 30 minutes. After lysis, the amount of adhered granulocytes was analyzed by measurement of myeloperoxidase activity.

### Flowcytometric Analysis

#### *Oxidative Burst*

Neutrophils were primed with dihydrorhodamine (1  $\mu$ mol/L) for 10 minutes.

#### *CD11b Surface Expression*

Granulocytes were incubated with a FITC-labeled anti-CD11b antibody (AbD Serotec, Düsseldorf, Germany).

#### *ICAM-1 Expression*

HUVECs were trypsinized, formalin-fixed, and incubated with a FITC-labeled anti-CD54 antibody (Biozol, Eching, Germany). Cells were analyzed with a FACSCanto II flow cytometer (Becton Dickinson, Heidelberg, Germany).

### ICAM-1 and Interleukin-8 mRNA Expression

HeLa cells were treated as indicated and ICAM-1/interleukin-8 mRNA expression was measured by real-time RT-PCR as previously described.<sup>23</sup>

### Quantification of Cell Death

*Apoptosis rates* were measured by determination of subdiploid DNA content as previously described.<sup>24</sup> Briefly, permeabilized cells were stained with propidium iodide and analyzed by flow cytometry on a FACSCalibur (Becton Dickinson). *General cell death rates* were quantified by staining nonpermeabilized cells with propidium iodide and subsequently analyzing the propidium iodide positive cells by flow cytometry.

### Western Blot Analysis

Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes (GE Healthcare, Munich, Germany) via electroblotting. The following antibodies were used: Phospho-TGF- $\beta$ -activated kinase 1 (TAK1), phospho-extracellular signal-regulated kinase, TNF receptor-associated factor 2 (TRAF2), phospho-p38, phospho-cJun N-terminal kinase (JNK), phospho-I $\kappa$ B $\alpha$ , ubiquitin, and receptor-interacting protein1 (RIP1; Cell Signaling/NEB, Frankfurt am Main, Germany). MAPK phosphatase-1, I $\kappa$ B $\alpha$ , p52 (NF $\kappa$ B), TRAF5 (Santa Cruz, Heidelberg, Germany), cIAP1 (R&D Systems, Wiesbaden, Germany), cIAP2 (Epitomics/Biomol, Hamburg, Germany), and XIAP (Becton Dickinson). Jurkat cell lysate was from Cell Signaling/NEB.

### Analysis of NF- $\kappa$ B p65 Intracellular Localization

Formalin-fixed HUVECs were incubated with an anti-NF $\kappa$ B p65 (Santa Cruz) primary and AlexaFluor 488-linked secondary antibody (Molecular Probes, Eugene, OR). The translocation of NF $\kappa$ B p65 was analyzed using a Zeiss LSM 510 Meta confocal laser scanning microscope (Zeiss, Oberkochen, Germany).

### Electrophoretic Mobility Shift Assay

Nuclear protein extracts were prepared from HUVECs and electrophoretic mobility shift assay was performed as previously described.<sup>25</sup>

### Dual Luciferase Reporter Assay

Firefly luciferase reporter vector pGL4.32[luc2P/NF- $\kappa$ B-RE/Hygro] and Renilla luciferase reporter vector pGL4.74[hRLuc/TK] were from Promega (Heidelberg, Germany). HUVECs were transfected using the Amaxa HUVEC Nucleofactor Kit (Lonza, Cologne, Germany). Luciferase activity was determined using the Dual Luciferase Reporter Assay System (Promega).

## Immunoprecipitation

HUVEC lysates were incubated with cIAP1 (R&D Systems) or RIP1 (Cell Signaling) antibody. Proteins were precipitated by adding Protein A agarose beads (Sigma-Aldrich). Proteins were extracted from the beads with Laemmli sample buffer and subjected to Western blot analysis.

## TAK1 Kinase Assay

Active TAK1 kinase was precipitated from cell lysates with TAK1 antibody (Cell Signaling). [ $\gamma$ - $^{32}$ P]ATP and the TAK1 substrate MAPK kinase 3 (Biaffin, Kassel, Germany) were added to start the kinase reaction. Samples were analyzed by SDS gel electrophoresis and phosphorylated MAPK kinase 3 was detected by autoradiography.

## Gene Silencing

HUVECs were transfected with XIAP siRNA (ON-TARGETplus SMARTpool siRNA), cIAP1 siRNA (ON-TARGETplus duplex siRNA), cIAP2 siRNA (ON-TARGETplus duplex siRNA) (Thermo Scientific/Dharmacon, Bonn, Germany), or with the corresponding nontargeting siRNA by electroporation using the Amaxa HUVEC Nucleofector kit (Amaxa/Lonza).

## Cytosol/Membrane Fractionation

Confluent HUVECs were treated as indicated, lysed, and separated into a soluble (cytosolic) and a particulate (membranous) fraction, as described previously by Li et al.<sup>26</sup>

## Statistical Analysis

Bar graph data represent means  $\pm$  SEM. Statistical analysis was performed with the GraphPad Prism software version 3.03 (GraphPad Software, San Diego, CA). Unpaired *t* test was used to compare 2 groups. To compare 3 or more groups, 1-way ANOVA followed by Bonferroni posthoc test was used.  $P \leq 0.05$  was considered as statistically significant.


## Results

### The IAP Inhibitor ABT Exhibits

#### Anti-Inflammatory Actions in Murine Models of Inflammation and Blocks Leukocyte Extravasation

The overall anti-inflammatory potential of ABT was tested in 2 different animal models of inflammation: (1) In the antigen-induced arthritis model, mice that were treated intraperitoneally with 5  $\mu$ g ABT per day did not evolve any joint swelling in the antigen-treated knee (Figure 1A). (2) In the ConA-evoked hepatitis model, ABT (1  $\mu$ g, IV) diminished ( $\approx 40\%$ ) the rise in the serum levels of alanine aminotransferase, a marker for liver cell injury (Figure 1B). Moreover, the ConA-provoked neutrophil recruitment to the liver, which crucially contributes to the liver injury, is reduced significantly when mice were treated with ABT as shown in histological images and by determining the neutrophil count (Figure 1C).


In postcapillary venules of the TNF $\alpha$ -treated mouse cremaster muscle, ABT affected leukocyte extravasation: The group of mice that was pretreated with 5  $\mu$ g ABT (IA) for 30 minutes showed a slight (nonsignificant) reduction of leukocyte adhesion ( $\approx 20\%$ ) and a strong decrease of leukocyte transmigration ( $\approx 60\%$ ) in comparison to the control group (Figure 1C). Leukocyte rolling, vessel diameter, blood flow velocity, wall shear rate, and systemic count of leukocytes were not influenced by ABT (data not shown).



**Figure 1.** Antagonist A-4.10099.1 (ABT) protects against antigen-induced arthritis, diminishes ConA-induced liver injury, and attenuates leukocyte extravasation in mice. **A**, Mice were immunized with methylated BSA (mBSA). One group was additionally treated IP with 5  $\mu$ g ABT every day beginning 2 days before the induction of the arthritis with mBSA in the left knee joint. The right knee joints were injected with NaCl solution (internal controls). The knee joint diameter was determined daily. Control mice:  $N=5$ . ABT-treated mice:  $N=6$ .  $*P \leq 0.05$  vs ABT+mBSA. **B**, **C**, Mice were treated IV with 1  $\mu$ g ABT 15 minutes before IV administration of 15 mg/kg ConA. Liver tissues were removed 8 hours after ConA application. ConA-treated mice:  $N=12$ . ConA+ABT-treated mice:  $N=12$ . **B**, Plasma levels of alanine transaminase (ALT) were assessed. **C**, Liver sections were stained for naphthol-AS-D-chloroacetate esterase to analyze neutrophil infiltration. Left: the bar graph shows the quantification of the neutrophil count in the liver sections.  $*P \leq 0.05$  vs ConA. Right: representative images. Black bar=100  $\mu$ m. **D**, Leukocyte recruitment to the mouse cremaster muscle was induced by intrascrotal injection of TNF $\alpha$  (500 ng) 4 hours before intravital microscopy. Five micrograms of ABT was injected IA 30 minutes before application of TNF $\alpha$ . During a 15-minute observation period, leukocyte adhesion and transmigration were assessed. TNF $\alpha$ -treated mice:  $N=5$ . ABT+TNF $\alpha$ -treated mice:  $N=5$ .  $*P \leq 0.05$  vs TNF $\alpha$ .

### IAP Inhibition Influences Leukocyte Adhesion to Endothelial Cells and Reduces TNF $\alpha$ -Induced ICAM-1 Expression

Aiming at mechanistic analyses, we confirmed the attenuation of leukocyte-EC interaction in vitro. The adherence of



**Figure 2.** Influence of antagonist A-4.10099.1 (ABT) on TNF $\alpha$ -induced leukocyte-endothelial cell interaction as well as on TNF $\alpha$ -activated pathways in endothelial cells, HeLa cells, and leukocytes. Human umbilical vein endothelial cells (HUVECs) were preincubated for 30 minutes with ABT (**A**) or with intercellular adhesion molecule-1 (ICAM-1) blocking antibody ( $\alpha$ CD54, 20  $\mu$ g) for 1 hour (**C**) and treated with TNF $\alpha$  (10 ng/mL) for 24 hours. Isolated human neutrophil granulocytes were added ( $10^5$  cells per well) and allowed to adhere for 45 minutes. Myeloperoxidase activity kinetics were measured to determine the amount of adhered granulocytes. **A**,  $N=7$ .  $^*P\leq 0.05$  vs TNF $\alpha$  alone. **B**, HUVECs were pretreated with ABT for 30 minutes and treated with TNF $\alpha$  (10 ng/mL) for 24 hours. The levels of ICAM-1 surface expression were determined by flow cytometry.  $N=3$ . **C**,  $N=3$ .  $^*P\leq 0.05$  vs TNF $\alpha$  alone. **D**, **E**, HeLa cells were treated with ABT (1  $\mu$ mol/L) for 30 minutes. TNF $\alpha$  (20 ng/mL) was applied for 3 hours. ICAM-1 (**D**;  $N=3$ ) and IL-8 (**E**;  $N=5$ ) mRNA expression were analyzed by real-time RT-PCR.  $^*P\leq 0.05$  vs TNF $\alpha$  alone. **F**, **G**, Isolated human neutrophil granulocytes were treated for 30 minutes with ABT before incubation with 100 nmol/L fMLP for 15 minutes. **F**, Granulocytes were loaded with 10  $\mu$ mol/L dihydrorhodamine and analyzed by flow cytometry.  $N=3$ . **G**, CD11b surface expression was measured by flow cytometry.  $N=3$ .  $^*P\leq 0.05$  vs fMLP alone.


freshly isolated human neutrophils to the EC monolayer was concentration-dependently reduced with an IC<sub>50</sub> value of  $\approx 10$  nmol/L (Figure 2A). Pretreatment of ECs with ABT resulted in a profound concentration-dependent downregulation of endothelial ICAM-1 surface protein expression with an IC<sub>50</sub> value of 18 nmol/L (Figure 2B). An ICAM-1-blocking antibody strongly reduced the adhesion of neutrophils to ECs, thus corroborating the essential role of ICAM-1 for neutrophil adhesion (Figure 2C). Moreover, ABT influences mRNA levels of both ICAM-1 (Figure 2D) and interleukin-8 (Figure 2E), as shown in HeLa cells. Regarding actions of ABT on neutrophils, ABT had no influence on the formyl-methionyl-leucyl-phenylalanine-induced production of reactive oxygen species (Figure 2F) and slightly reduced the expression of CD11b (Figure 2G). These findings indicate

that ABT, besides strongly acting on ECs, might also affect neutrophil activation.

### The Effect of ABT on ICAM-1 Expression Can Be Mimicked by Structurally Different IAP Inhibitors and Is Not Due to Increased Apoptosis or Caspase Activation

Two IAP antagonists structurally different from ABT, the monomeric Smac mimetic Smac066 and the homodimeric Smac085, effectively reduced the TNF $\alpha$ -evoked ICAM-1 expression (Figure 3A), suggesting that the action of ABT is not a specific feature of this individual compound due to side or off-target effects. As assessed by measuring the rate of apoptosis (subdiploid DNA content), ABT treatment for 24 and 48 hours did not cause any induction of apoptosis (Figure





**Figure 3.** The effect of antagonist A-4.10099.1 (ABT) on intercellular adhesion molecule-1 (ICAM-1) expression can be mimicked by structurally different inhibitor of apoptosis protein (IAP) inhibitors and is not due to increased apoptosis or caspase activation. **A**, Human umbilical vein endothelial cells (HUVECs) were treated with Smac066 (monovalent) or Smac085 (bivalent) for 30 minutes before incubation with TNF $\alpha$  (10 ng/mL) for 24 hours. The levels of ICAM-1 surface protein expression were determined by flow cytometry.  $N=3$ . \* $P\leq 0.05$  vs TNF $\alpha$  alone. **B**, HUVECs were treated with ABT for 24 or 48 hours or they were pretreated with ABT for 30 minutes before incubation with TNF $\alpha$  (10 ng/mL) for 24 hours. Subdiploid DNA content was determined by flow cytometry.  $N=3$ . **C**, HUVECs were pretreated for 30 minutes with ABT and subsequently treated with TNF $\alpha$  (10 ng/mL) for 24 or 48 hours. Cells were then incubated with propidium iodide (PI; 10  $\mu$ g/mL) for 30 minutes. PI positive cells were analyzed by flow cytometry. Cells permeabilized with Triton X-100 (0.1%) were used as a positive control.  $N=3$ . **D**, HUVECs were pretreated with the pan-caspase inhibitor Q-VD-OPh (10  $\mu$ mol/L, 30 minutes) before treatment with ABT (100 nmol/L) for 30 minutes and TNF $\alpha$  (10 ng/mL) for 24 hours. The levels of ICAM-1 surface protein expression were determined by flow cytometry.  $N=3$ . \* $P\leq 0.05$  vs TNF $\alpha$  alone.

3B, left and middle panel). Even the additional presence of TNF $\alpha$  for 24 hours did not evoke apoptotic cell death (Figure 3B, right panel). Moreover, by quantification of propidium iodide-positive cells after 24 and 48 hours of treatment with ABT and TNF (Figure 3C), we revealed that the IAP antagonist does not trigger cell death in HUVECs. Thus, it can be excluded that the effects of ABT on ECs are simply due apoptosis induction. Furthermore, it can also be excluded that caspases participate in the action of ABT on the TNF $\alpha$ -induced ICAM-1 expression: Figure 3D shows that the application of a pan-caspase inhibitor (Q-VD-OPh) had no impact on this effect.

### ABT Does Not Interfere With the Endothelial NF $\kappa$ B Signaling


NF $\kappa$ B is the major transcription factor that regulates ICAM-1 expression; however, as shown in Figure 4A, ABT did neither influence the phosphorylation of the NF $\kappa$ B inhibitor I $\kappa$ B $\alpha$ , nor its degradation evoked by TNF $\alpha$ . Also, both the TNF $\alpha$ -induced translocation of the NF $\kappa$ B subunit p65 to the nucleus (Figure 4B) and the DNA-binding capacity of NF $\kappa$ B were left unaffected by ABT (Figure 4C). Besides this canonical way of NF $\kappa$ B activation, ABT treatment did also not lead to an induction of the noncanonical NF $\kappa$ B signaling, because neither ABT alone nor in combination with TNF $\alpha$  did evoke the processing of p100 to p52 (Figure 4D). Finally, the TNF $\alpha$ -evoked NF $\kappa$ B-dependent gene expression was not affected by ABT in a dual-luciferase reporter gene assay (Figure 4E, left). Curcumin, which is known to inhibit NF $\kappa$ B

signaling by blocking I $\kappa$ B $\alpha$  phosphorylation,<sup>27</sup> was used as a positive control (Figure 4E, right).

### IAP Inhibition Affects Endothelial MAPK Signaling

Figure 5A shows that ABT diminished the TNF $\alpha$ -induced phosphorylation of the MAPKs p38 and JNK, but not of extracellular signal-regulated kinase, and did not affect the protein levels of the MAPK phosphatase-1. Pharmacological inhibition of p38 and JNK resulted in a significant decrease of TNF $\alpha$ -induced ICAM-1 expression (Figure 5B). The added levels of ICAM-1 reduction caused by the 2 inhibitors SP600125 (JNK) and SB203580 (p38) nicely correspond to the level caused by ABT. In addition, ABT affects the p38- and JNK-activating MAP3K TAK1: The TNF $\alpha$ -induced phosphorylation of TAK1, indicating its activation, was reduced when cells were pretreated with the IAP antagonist (Figure 5C). Moreover, by performing a TAK1 kinase assay that uses MAPK kinase 3 as a TAK1 substrate, we could confirm the inhibitory action of ABT treatment on the TNF $\alpha$ -triggered TAK1 activity (Figure 5D). Taken together, ABT inhibited the TNF $\alpha$ -induced activation of p38, JNK, and TAK1.

**Targeting of cIAP1 and cIAP2, But Not of XIAP, Accounts for the ICAM-1-Reducing Effect of ABT**  
We tested whether gene silencing of XIAP, cIAP1, or cIAP2 results in similar effects on ICAM-1 expression as treating ECs with the IAP antagonist. Surprisingly, a reduction of endothelial XIAP levels on transfection of siRNA resulted in



**Figure 4.** Antagonist A-4.10099.1 (ABT) does not interfere with the endothelial NFκB signaling. **A, D,** HUVECs were pretreated with ABT (100 nmol/L) for 30 minutes and subsequently treated with TNFα (10 ng/mL). Levels of IκBα, phospho-IκBα, and actin (**A**) or levels of p100, p52, and actin (**D**) were determined by Western blotting. Jurkat lysates were used as positive control (**D**). One representative out of 3 independently performed experiments is shown, each. **B,** NFκB p65 subunit was visualized via immunocytochemistry. White bar=40 μm. One representative out of 3 independently performed experiments is shown, each. **C,** NFκB DNA-binding activity was measured by electrophoretic mobility shift assay. One representative out of 3 independently performed experiments is shown, each. **E,** TNFα was applied for 6 hours. The well-known NFκB inhibitor curcumin (curc, 20 μmol/L, 30 minutes pretreatment) served as positive control. NFκB promoter activity was analyzed by dual luciferase reporter gene assay. *N*=3. \**P*≤0.05 vs TNF.

a huge increase of ICAM-1 expression and ABT was still capable of reducing ICAM-1 levels (Figure 5E, left). Interestingly, these cells exhibited strongly increased protein levels of cIAP1 and cIAP2 (Figure 5E, right). Nevertheless, silencing of cIAP1, cIAP2, and of both significantly reduced

TNFα-induced ICAM-1 expression (Figure 5F). Of note, the degree of reduction is similar to that achievable with ABT. These results suggest that the presence of XIAP is not required for the effects of the IAP antagonist and that cIAP1 and cIAP2 are involved in the regulation of TNFα-induced ICAM-1 expression.

### ABT Interferes With the TNF Receptor Proximal Signaling

The fact that silencing of cIAP1 and cIAP2, but not of XIAP, reduced ICAM-1 expression gave rise to the question in which way the Smac mimetic influences the activation of p38 and JNK. We analyzed the action of ABT on the protein levels of XIAP, cIAP1, and cIAP2 and found a rapid and sustained reduction of cIAP1, whereas XIAP levels were not affected (Figure 6A). Protein levels of cIAP2 and their reduction by ABT could only be detected when its expression was induced by TNFα for a longer period of time (24 hours) as shown in Figure 6C. Furthermore, we could demonstrate that the IAP antagonist leads to a fast and strong ubiquitination of cIAP1 and cIAP2 (Figure 6B). The pharmacological proteasome inhibitor MG132 abolished the ABT-evoked disappearance of cIAP1 and cIAP2 (Figure 6C) and, most importantly, abrogated the effects of ABT on the TNFα-induced expression of ICAM-1 (Figure 6D), indicating that proteasomal degradation is important for these events.


cIAP1 and cIAP2 have been described as members of the TNFR signaling complex.<sup>28</sup> We hypothesized that the degradation of cIAP1/2 mediated by ABT influences this complex. TRAF2 is known to mediate the activation of NFκB and MAP3K signaling<sup>29</sup> and was reported to interact with cIAP1/2.<sup>30</sup> ABT triggers an immediate decrease of TRAF2 protein levels in endothelial membrane fractions (Figure 6E). In contrast, TRAF5, which can compensate the loss of TRAF2 in terms of activation of the NFκB signaling,<sup>31,32</sup> was not affected by ABT (Figure 6E).

Moreover, as shown in Figure 6F, the IAP antagonist led to a reduced ubiquitination of the TNF receptor-associated kinase RIP1, which is known to be essential for the TNFα-mediated activation of TAK1.<sup>9</sup>


In summary, our data indicate that ABT induces the ubiquitination and proteasomal degradation of cIAP1/2, which is accompanied by an altered ratio of the levels of TRAF2 and TRAF5 at the EC membrane and by an altered ubiquitination status of the TAK1 activator RIP1.

### Discussion

Activation of inflammatory processes is crucial for the host defense against infections and for repairing tissue damage, but it shows destructive properties in chronic pathological conditions like atherosclerosis, rheumatoid arthritis, or ischemia. The administration of conventional anti-inflammatory therapeutics, such as glucocorticoids or nonsteroidal anti-inflammatory drugs, is not always effective and often causes severe side effects. Consequently, inflammation is still a very important subject of research in terms of unraveling novel signaling interconnections in order to develop new therapeutic strategies. IAPs have been increasingly recognized to affect NFκB signaling<sup>6</sup> and to be part of the TNF receptor-



**Figure 5.** IAP inhibition affects endothelial mitogen-activated protein kinases (MAPK) signaling and silencing of cellular inhibitor of apoptosis protein 1/2 (cIAP1/2), but not of X-linked inhibitor of apoptosis protein (XIAP), inhibits intercellular adhesion molecule-1 (ICAM-1) expression. **A**, Human umbilical vein endothelial cells (HUVECs) were treated with 100 nmol/L ABT for 30 minutes before incubation with 10 ng/mL TNF $\alpha$ . Levels of phospho-p38 mitogen-activated protein kinase (MAPK), phospho-c-Jun N-terminal kinase (JNK), phospho-extracellular signal-regulated kinase (ERK), MAPK phosphatase-1 (MKP-1), and actin were analyzed by Western blotting. One representative out of 3 independently performed experiments is shown, each. **B**, HUVECs were treated with ABT (100 nmol/L), the p38 MAPK inhibitor SB203580 (20  $\mu$ mol/L), and the JNK inhibitor SP600125 (10  $\mu$ mol/L) for 30 minutes followed by TNF $\alpha$  (10 ng/mL) for 24 hours. Levels of ICAM-1 surface expression were determined by flow cytometry.  $N=3$ . \* $P\leq 0.05$  vs TNF $\alpha$  alone. **C**, **D**, HUVECs were pretreated with ABT for 30 minutes followed by 5 minutes TNF $\alpha$  (10 ng/mL) treatment. Levels of phospho-TGF- $\beta$ -activated kinase 1 (TAK1) and actin were determined by Western blotting (**C**). TAK1 was precipitated from cell lysates and, after performing a TAK1 kinase activity assay, levels of the phosphorylated TAK1 substrate MAPK kinase 3 were detected by autoradiography on gel electrophoresis (**D**). One representative out of 3 independently performed experiments is shown, each. **E**, **F**, HUVECs were transfected with nontargeting (nt) or specific siRNA against cIAP1, cIAP2, and XIAP. Cells were then treated with ABT (100 nmol/L, 30 minutes) and TNF $\alpha$  (10 ng/mL, 24 hours). Levels of ICAM-1 surface expression were determined by flow cytometry.  $N=3$ . Levels of X-linked inhibitor of apoptosis protein (XIAP), cIAP1, cIAP2, and actin were analyzed by Western blotting. One representative out of 3 independently performed experiments is shown, each. \* $P\leq 0.05$  vs TNF $\alpha$  alone.



**Figure 6.** Antagonist A-4.10099.1 (ABT) interacts with the TNF receptor signaling. **A**, Human umbilical vein endothelial cells (HUVECs) were treated with ABT (100 nmol/L). Levels of cellular inhibitor of apoptosis protein 1 (cIAP1), X-linked inhibitor of apoptosis protein (XIAP), and actin were analyzed by Western blotting. One representative out of 3 independently performed experiments is shown. **B**, After 30 minutes pretreatment of HUVECs with ABT (100 nmol/L) and subsequent treatment with TNF $\alpha$  (10 ng/mL), levels of cIAP1 were analyzed by Western blot (upper panel). Additionally, cIAP1 was precipitated from cell lysates of HUVECs that were pretreated with the proteasome inhibitor MG132 (10  $\mu$ mol/L, 30 minutes) before treatment with ABT and TNF. Levels of ubiquitinated (Ub) cIAP1 and of precipitated cIAP1 were determined by Western blotting (middle and lower panel). One representative out of 3 independently performed experiments is shown, each. **C**, **D**, HUVECs were pretreated with the proteasome inhibitor MG132 (10  $\mu$ mol/L, 30 minutes) before treatment with ABT (1  $\mu$ mol/L) for 30 minutes and TNF $\alpha$  (10 ng/mL) for 24 hours. The levels of cIAP1, cIAP2, XIAP, and actin were determined by Western blotting. One representative out of 3 independently performed experiments is shown, each. **E**, Levels of ICAM-1 surface expression were determined by flow cytometry.  $N=3$ . **D**, **E**, HUVECs were treated with ABT (1  $\mu$ mol/L, 30 minutes) followed by TNF $\alpha$  (10 ng/mL) for 5 minutes. Cells were then fractionated into cytosol and membrane fractions. The levels of TNF receptor-associated factors 2 and 5, cIAP1, and actin were determined by Western blotting. One representative out of 3 independently performed experiments is shown, each. **F**, Cells were treated with ABT for 30 minutes (100 nmol/L) and subsequently incubated with TNF $\alpha$  (10 ng/mL). Receptor-interacting protein1 (RIP1) was precipitated from cell lysates and levels of ubiquitinated and precipitated RIP1 were analyzed by Western blotting. One representative out of 3 independently performed experiments is shown.

associated complex.<sup>8,30</sup> Besides their role in the regulation of cell survival, there is upcoming evidence that the IAPs are also involved in the regulation of immune functions.<sup>12</sup> In the present work, we demonstrate that IAP inhibitors could open a new and promising anti-inflammatory approach.

In vivo, the IAP antagonist exerted a profound anti-inflammatory effect in an antigen-induced arthritis model and, moreover, inhibited liver injury and leukocyte infiltration in a ConA-evoked hepatitis model in mice. Also leukocyte-EC interactions were significantly attenuated in vivo. The dosing of ABT used in the in vivo models was deduced from the concentrations that caused both the maximum inhibition of ICAM-1 expression and a significant inhibition of leukocyte adhesion in vitro (1  $\mu$ mol/L). In the arthritis model, ABT was applied IP at 250  $\mu$ g/kg/d. Based on the theoretical assumption of an immediate and complete absorption, this dosage could generate a maximum plasma level of 10  $\mu$ mol/L. Regarding the administration of 50  $\mu$ g/kg ABT directly into the circulation in the hepatitis and cremas-

ter model, a maximum ABT plasma level of 2  $\mu$ mol/L could be achieved. Noteworthy, subcutaneously applied doses of up to 40 mg/kg/d ABT are tolerable in mice.<sup>5</sup>

Until now, IAP antagonists have only been applied in vivo to proof them as promising candidates for anticancer therapy: ABT was successfully used in a murine breast cancer xenograft tumor model<sup>5</sup> and, noteworthy, some Smac mimetics have already entered phase I clinical trials.<sup>33</sup> Our work, however, is the first study that investigates the anti-inflammatory action of an IAP antagonist in the context of leukocyte-EC interaction, both in vivo and in vitro. On the basis of the profound in vivo actions of ABT, we used this compound as a tool to uncover the role of IAPs in inflammatory processes of ECs.

The up-regulation of EC adhesion molecule expression is a hallmark of inflammatory processes. Endothelial cell adhesion molecules are crucial for leukocyte recruitment to sites of inflammation and they tightly regulate the different stages of rolling, adhesion, and transmigration (diapedesis) of leu-



kocytes.<sup>34</sup> We infer from our data that the IAP antagonist impairs leukocyte adhesion by inhibiting the expression of ICAM-1 on ECs, because blocking of ICAM-1 on the EC surface by a neutralizing antibody clearly lowered leukocyte adhesion.

Interestingly, the activation of the canonical NF $\kappa$ B pathway, which plays a pivotal role in the upregulation of ICAM-1, is not targeted by ABT. ABT did also not alter the noncanonical NF $\kappa$ B signaling. This is in contrast to studies showing that IAP antagonists can activate this signaling pathway in other cell types.<sup>35,36</sup> Instead, ABT inhibited the activation of the MAPKs p38 and JNK, which have been reported to regulate cell adhesion molecules<sup>37</sup> by activation of different transcription factors.<sup>38</sup> The fact that inhibitors of JNK and p38 significantly reduce TNF $\alpha$ -triggered ICAM-1 expression in ECs suggests that ABT blocks cell adhesion molecule expression predominantly via an inhibition of these 2 MAP kinases but not via affecting NF $\kappa$ B signaling.

The IAP-antagonist ABT, which was modeled to bind to the BIR3 domain of XIAP, reduced the phosphorylation of the MAP3K TAK1 (upstream of JNK and p38). However, silencing of XIAP did not result in an anti-inflammatory effect, but it even amplified TNF $\alpha$ -induced ICAM-1 expression and caused an increase in the levels of cIAP1 and cIAP2. This compensatory upregulation of cIAP1 and cIAP2 has also been reported in XIAP knockout mice.<sup>39</sup> In contrast, the reduction of cIAP1 and/or cIAP2 levels by RNAi led to an inhibition of the TNF-induced ICAM-1 that is comparable to the degree of inhibition caused by ABT. Correspondingly, the IAP antagonist itself evoked a decrease of cIAP1 and cIAP2, but not of XIAP levels in ECs. Monovalent Smac mimetics, such as ABT or Smac066, were designed to mimic the Smac AVPI-binding motif to target the BIR3 domain of XIAP. Nevertheless, it has been shown that this kind of mimetics also exhibit high affinities to the BIR3 domains of cIAP1 and cIAP2.<sup>41</sup> Interaction of Smac mimetics with cIAPs influences their E3-ligase and auto-ubiquitination activity and results in proteasomal degradation of cIAP1/2, whereas XIAP levels are not affected.<sup>35,36,39–41</sup> We could demonstrate that ABT induces ubiquitination of cIAP1, which goes along with the loss of this protein. The exact mode of action of Smac mimetics in this context has not been elucidated yet. However, Darding et al<sup>42</sup> suggested that Smac mimetic-induced auto-ubiquitination of cIAPs requires TRAF2 as scaffolding protein to mediate dimerization of the cIAP RING domain, which supports their E3-ligase activity. Our findings suggest that the anti-inflammatory effect of ABT does not arise from antagonizing XIAP but is connected to the proteasomal degradation of cIAP1 and cIAP2, which is nicely reflected in the results of the cIAP1/2 silencing experiments. Interestingly, cIAP1 and cIAP2 knockout mice are asymptomatic, which might be due to the observed mutual upregulation due to compensatory mechanisms.<sup>13,43</sup> Unfortunately, a cIAP1/2 double knockout mouse, in which the effects of ABT might be mimicked, is not available. However, the importance of influencing cIAP1/2 levels for the anti-inflammatory action of the IAP antagonist is affirmed by our finding that upregulation of cIAP1 and cIAP2 levels in response to XIAP silencing strongly increases endothelial activation.

Moreover, we found that the reduction of cIAP1 and cIAP2 protein levels influences TNFR signaling and, as a consequence, the activation of the MAP3K TAK1. The TNF $\alpha$ -induced activation of TNFR involves the assembly of the so-called TNFR-associated complex resulting in an activation of NF $\kappa$ B and MAPK signaling. The recruitment of TRADD and TRAF2, cIAP1/2 and RIP,<sup>29</sup> as well as the degradative and nondegradative ubiquitination processes exerted by the E3 ligase function of TRAF2 and cIAP1/2 provide platforms for the recruitment and activation of the I $\kappa$ B kinase and the TAB/TAK complex.<sup>28</sup> cIAP1/2 can directly interact with the adaptor protein TRAF2 and with RIP1,<sup>9,30</sup> which function both in NF $\kappa$ B and MAPK signaling.<sup>35,44–46</sup> It has been reported that the auto-ubiquitination-dependent degradation of cIAP1 and cIAP2 induced by IAP antagonists completely abrogates NF $\kappa$ B signaling.<sup>10,11</sup> In contrast, it has also been described that cIAP1/2 degradation evoked by a Smac mimetic is able to stimulate NF $\kappa$ B signaling.<sup>36,47</sup> In our setting, the treatment of ECs with an IAP antagonist resulted in a proteasome-dependent degradation of cIAP1 and cIAP2 but not in an alteration of NF $\kappa$ B activation. Instead, we detected a loss of TRAF2 in the EC membrane fraction mediated by ABT suggesting that the degradation of cIAP1/2 influences the TNF $\alpha$ -induced MAPK activation by affecting TRAF2 in the TNFR-associated signaling complex. However, there was no TNF $\alpha$ -evoked increase of TRAF2 in the membrane fractions, as it could have been expected, but nevertheless our finding is in accordance with the study of Yeh et al reporting that a loss of TRAF2 prevents TNF $\alpha$ -caused activation of JNK.<sup>32</sup> Moreover, we found a reduction of RIP1 ubiquitination in ABT-treated ECs. Bertrand et al<sup>9</sup> showed that cIAP1/2 can directly ubiquitinate RIP1 and that TRAF2 needs to be present for proper ubiquitination of RIP1. In the absence of the cIAPs, the association of RIP1 with TAK1 was impaired, which affected TAK1 signaling. Because TAK1 not only accounts for an activation of MAPK, but also of I $\kappa$ B kinase and thus NF $\kappa$ B,<sup>48</sup> the question arises of how MAPK signaling is impaired by ABT, whereas NF $\kappa$ B signaling remains unaffected. In contrast to TRAF2, the level of TRAF5 in membrane fraction did not change. In knock-out mice, TRAF5 has been found to compensate for the absence of TRAF2 concerning the activation of NF $\kappa$ B, but not in regard to the activation of the MAPK signaling.<sup>31,32</sup> This strongly supports our hypothesis that the degradation of cIAP1 and cIAP2 in the TNFR-associated signaling complex goes along with an impaired initiation of MAPK signaling. Thus, the inflammatory activation of ECs is abrogated, whereas NF $\kappa$ B signaling is not impaired. This may explain why HUVECs did not die on treatment with ABT and TNF as it has been described for cancer cells<sup>36</sup>: The unaffected, ongoing NF $\kappa$ B activation still can mediate a prosurvival signaling.

Inflammation and the regulation of cell death are often closely connected, not only in the development and progression of cancer, but also in pathologies like atherosclerosis.<sup>49</sup> For example, Moran and Agrawal showed an upregulation of IAPs in atherosclerotic plaques of patients with carotid stenosis.<sup>50</sup> Therefore, it could be speculated that targeting IAPs might possess the potential to dually influence inflammatory diseases like atherosclerosis, ie, by suppressing in-

flammatory endothelial signaling processes as well as inducing apoptosis of proliferating vascular smooth muscle cells and infiltrating immune cells. Most interestingly, Tseng et al<sup>51</sup> describes elimination of cIAPs in macrophages as a highly specific tool to inhibit proinflammatory genes without affecting the anti-inflammatory and tumor suppressive IFN response and suggests IAP antagonists as potentially promising anti-inflammatory drugs.

In summary, our study provides for the first time evidence that IAP-inhibiting compounds possess profound anti-inflammatory properties in vivo. Moreover, we could show that IAPs play an important regulatory role in the inflammatory activation of ECs and, most importantly, that this might open a novel therapeutic strategy for the treatment of inflammation-associated diseases.

### Acknowledgments

The compound A-4.10099.1 (ABT) was kindly provided by Abbott Bioresearch Corporation, Worcester, MA. The excellent work of Bianca Hager, Jana Peliskova, and Rita Socher is thankfully acknowledged.

### Sources of Funding

None.

### Disclosures

None.

### References

- Scott FL, Denault JB, Riedl SJ, Shin H, Renatus M, Salvesen GS. XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. *EMBO J*. 2005;24:645–655.
- Shiozaki EN, Chai J, Rigotti DJ, Riedl SJ, Li P, Srinivasula SM, Alnemri ES, Fairman R, Shi Y. Mechanism of XIAP-mediated inhibition of caspase-9. *Mol Cell*. 2003;11:519–527.
- Krepela E, Dankova P, Moravcikova E, Krepelova A, Prochazka J, Cermak J, Schutzner J, Zatloukal P, Benkova K. Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. *Int J Oncol*. 2009;35:1449–1462.
- Sung KW, Choi J, Hwang YK, Lee SJ, Kim HJ, Kim JY, Cho EJ, Yoo KH, Koo HH. Overexpression of X-linked inhibitor of apoptosis protein (XIAP) is an independent unfavorable prognostic factor in childhood de novo acute myeloid leukemia. *J Korean Med Sci*. 2009;24:605–613.
- Oost TK, Sun C, Armstrong RC, Al-Assaad AS, Betz SF, Deckwerth TL, Ding H, Elmore SW, Meadows RP, Olejniczak ET, Oleksijew A, Oltersdorf T, Rosenberg SH, Shoemaker AR, Tomaselli KJ, Zou H, Fesik SW. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. *J Med Chem*. 2004;47:4417–4426.
- Lu M, Lin SC, Huang YH, Kang YJ, Rich R, Lo YC, Myszkowski D, Han JH, Wu H. XIAP induces NF-kappa B activation via the BIR1/TAB1 interaction and BIR1 dimerization. *Molecular Cell*. 2007;26:689–702.
- Sanna MG, da Silva Correia J, Ducey O, Lee J, Nomoto K, Schrantz N, Deveraux QL, Ulevitch RJ. IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. *Molecular and Cellular Biology*. 2002;22:1754–1766.
- Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. *Cell*. 1995;83:1243–1252.
- Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreau A, Durkin J, Gillard JW, Jaquith JB, Morris SJ, Barker PA. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. *Mol Cell*. 2008;30:689–700.
- Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, Arora V, Mak TW, Lacasse EC, Waring J, Korneluk RG. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. *Proc Natl Acad Sci U S A*. 2008;105:11778–11783.
- Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K, Fairbrother WJ, Vucic D. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. *J Biol Chem*. 2008;283:24295–24299.
- Silke J, Brink R. Regulation of TNFRSF and innate immune signalling complexes by TRAFs and cIAPs. *Cell Death Differ*. 2010;17:35–45.
- Conte D, Holcik M, Lefebvre CA, Lacasse E, Picketts DJ, Wright KE, Korneluk RG. Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. *Mol Cell Biol*. 2006;26:699–708.
- Bertrand MJ, Doiron K, Labbe K, Korneluk RG, Barker PA, Saleh M. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. *Immunity*. 2009;30:789–801.
- Bauler LD, Duckett CS, O'Riordan MX. XIAP regulates cytosol-specific innate immunity to Listeria infection. *PLoS Pathog*. 2008;4:e1000142.
- Aggarwal BB, Shishodia S, Ashikawa K, Bharti AC. The role of TNF and its family members in inflammation and cancer: lessons from gene deletion. *Curr Drug Targets Inflamm Allergy*. 2002;1:327–341.
- Seneci P, Bianchi A, Battaglia C, Belvisi L, Bolognesi M, Caprini A, Cosu F, Franco E, Matteo M, Delia D, Drago C, Khaled A, Lecis D, Manzoni L, Marizzoni M, Mastrangelo E, Milani M, Motto I, Moroni E, Potenza D, Rizzo V, Servida F, Turlizzi E, Varrone M, Vasile F, Scolastico C. Rational design, synthesis and characterization of potent, non-peptide Smac mimics/XIAP inhibitors as proapoptotic agents for cancer therapy. *Bioorg Med Chem*. 2009;17:5834–5856.
- Veihelmann A, Hofbauer A, Krombach F, Dorger M, Maier M, Refior HJ, Messmer K. Differential function of nitric oxide in murine antigen-induced arthritis. *Rheumatology*. 2002;41:509–517.
- Tiesges G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. *The Journal of Clinical Investigation*. 1992;90:196–203.
- Mempel TR, Moser C, Hutter J, Kuebler WM, Krombach F. Visualization of leukocyte transendothelial and interstitial migration using reflected light oblique transillumination in intravital video microscopy. *J Vasc Res*. 2003;40:435–441.
- Fürst R, Zahler S, Vollmar AM. Dexamethasone-induced expression of endothelial mitogen-activated protein kinase phosphatase-1 involves activation of the transcription factors activator protein-1 and 3',5'-cyclic adenosine 5'-monophosphate response element-binding protein and the generation of reactive oxygen species. *Endocrinology*. 2008;149:3635–3642.
- Hoffmann E, Thieffes A, Buhrow D, Dittrich-Breiholz O, Schneider H, Resch K, Kracht M. MEK1-dependent delayed expression of Fos-related antigen-1 counteracts c-Fos and p65 NF-kappaB-mediated interleukin-8 transcription in response to cytokines or growth factors. *J Biol Chem*. 2005;280:9706–9718.
- Wolter S, Doerrie A, Weber A, Schneider H, Hoffmann E, von der Ohe J, Bakiri L, Wagner EF, Resch K, Kracht M. c-Jun controls histone modifications, NF-kappaB recruitment, and RNA polymerase II function to activate the ccl2 gene. *Mol Cell Biol*. 2008;28:4407–4423.
- Lopez-Anton N, Rudy A, Barth N, Schmitz ML, Pettit GR, Schulze-Osthoff K, Dirsch VM, Vollmar AM. The marine product cephalostatin 1 activates an endoplasmic reticulum stress-specific and apoptosome-independent apoptotic signaling pathway. *J Biol Chem*. 2006;281:33078–33086.
- Kiemer AK, Weber NC, Vollmar AM. Induction of IkappaB: atrial natriuretic peptide as a regulator of the NF-kappaB pathway. *Biochem Biophys Res Commun*. 2002;295:1068–1076.
- Li H, Oehrlein SA, Wallerath T, Ihrig-Biedert I, Wohlfart P, Ulschöfer T, Jessen T, Herget T, Forstermann U, Kleinert H. Activation of protein kinase C alpha and/or epsilon enhances transcription of the human endothelial nitric oxide synthase gene. *Mol Pharmacol*. 1998;53:630–637.
- Divya CS, Pillai MR. Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. *Molecular carcinogenesis*. 2006;45:320–332.
- Haas TL, Emmerich CH, Gerlach B, Schmukle AC, Cordier SM, Rieser E, Feltham R, Vince J, Warnken U, Wenger T, Koschny R, Komander D, Silke J, Walczak H. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. *Mol Cell*. 2009;36:831–844.
- Devin A, Cook A, Lin Y, Rodriguez Y, Kelliher M, Liu ZG. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. *Immunity*. 2000;12:419–429.

30. Vince JE, Pantaki D, Feltham R, Mace PD, Cordier SM, Schmukle AC, Davidson AJ, Callus BA, Wong WW, Gentle IE, Carter H, Lee EF, Walczak H, Day CL, Vaux DL, Silke J. TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf- $\kappa$ B and to prevent tnf-induced apoptosis. *J Biol Chem*. 2009;284:35906–35915.
31. Tada K, Okazaki T, Sakon S, Koburai T, Kurosawa K, Yamaoka S, Hashimoto H, Mak TW, Yagita H, Okumura K, Yeh WC, Nakano H. Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death. *J Biol Chem*. 2001;276:36530–36534.
32. Yeh WC, Shahinian A, Speiser D, Kraunus J, Billia F, Wakeham A, de la Pompa JL, Ferrick D, Hum B, Iscove N, Ohashi P, Rothe M, Goeddel DV, Mak TW. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. *Immunity*. 1997;7:715–725.
33. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk DG. IAP-targeted therapies for cancer. *Oncogene*. 2008;27:6252–6275.
34. Madge LA, Pober JS. TNF signaling in vascular endothelial cells. *Exp Mol Pathol*. 2001;70:317–325.
35. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, Flygare JA, Fairbrother WJ, Deshayes K, Dixit VM, Vucic D. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. *Cell*. 2007;131:669–681.
36. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, Brink R, Leverkus M, Tergaonkar V, Schneider P, Callus BA, Koentgen F, Vaux DL, Silke J. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. *Cell*. 2007;131:682–693.
37. Lin SJ, Shyue SK, Hung YY, Chen YH, Ku HH, Chen JW, Tam KB, Chen YL. Superoxide dismutase inhibits the expression of vascular cell adhesion molecule-1 and intracellular cell adhesion molecule-1 induced by tumor necrosis factor-alpha in human endothelial cells through the JNK/p38 pathways. *Arterioscler Thromb Vasc Biol*. 2005;25:334–340.
38. Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. *J Leukoc Biol*. 1999;66:876–888.
39. Harlin H, Reffey SB, Duckett CS, Lindsten T, Thompson CB. Characterization of XIAP-deficient mice. *Mol Cell Biol*. 2001;21:3604–3608.
40. Cossu F, Malvezzi F, Canevari G, Mastrangelo E, Lecis D, Delia D, Seneci P, Scolastico C, Bolognesi M, Milani M. Recognition of Smac-mimetic compounds by the BIR domain of cIAP1. *Protein Science: A Publication of the Protein Society*. 2010;19:2418–2429.
41. Mannhold R, Fulda S, Carosati E. IAP antagonists: promising candidates for cancer therapy. *Drug Discov Today*. 2010;15:210–219.
42. Darding M, Feltham R, Tenev T, Bianchi K, Benetatos C, Silke J, Meier P. Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. *Cell Death and Differentiation*. In press.
43. Conze DB, Albert L, Ferrick DA, Goeddel DV, Yeh WC, Mak T, Ashwell JD. Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. *Mol Cell Biol*. 2005;25:3348–3356.
44. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. *Mol Cell*. 2006;22:245–257.
45. Varfolomeev E, Wayson SM, Dixit VM, Fairbrother WJ, Vucic D. The inhibitor of apoptosis protein fusion c-IAP2.MALT1 stimulates NF-kappaB activation independently of TRAF1 AND TRAF2. *J Biol Chem*. 2006;281:29022–29029.
46. Wu CJ, Conze DB, Li T, Srinivasula SM, Ashwell JD. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. *Nat Cell Biol*. 2006;8:398–406.
47. Ndubaku C, Varfolomeev E, Wang L, Zobel K, Lau K, Elliott LO, Maurer B, Fedorova AV, Dynek JN, Koehler M, Hymowitz SG, Tsui V, Deshayes K, Fairbrother WJ, Flygare JA, Vucic D. Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. *ACS Chem Biol*. 2009;4:557–566.
48. Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, Lee KY, Bussey C, Steckel M, Tanaka N, Yamada G, Akira S, Matsumoto K, Ghosh S. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. *Genes & Development*. 2005;19:2668–2681.
49. Karin M. Nuclear factor-kappaB in cancer development and progression. *Nature*. 2006;441:431–436.
50. Moran EP, Agrawal DK. Increased expression of inhibitor of apoptosis proteins in atherosclerotic plaques of symptomatic patients with carotid stenosis. *Exp Mol Pathol*. 2007;83:11–16.
51. Tseng PH, Matsuzawa A, Zhang W, Mino T, Vignali DA, Karin M. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. *Nature Immunology*. 2010;11:70–75.